Table 4.
Commercialized Liposomes Formulation | Commercial Name | Author (Year) |
---|---|---|
PEGylated liposomal doxorubicin | (Doxil/Caelyx) | Gabizon et al. (2003) [34] |
Non-PEGylated liposomal doxorubicin | (Myocet) | Rivankar (2014) [35] |
Liposomal daunorubicin | (DaunoXome) | Petre, Dittmer (2007) [36] |
Liposomal cytarabine | (DepoCyt) | Bomgaars et al. (2004) [37] |